Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

1. An Italian multidisciplinary Delphi Consensus on new insights about the clinical relevance of Pidotimod.Multidisciplinary respiratory medicine · 2025
   Article
2. Efficacy and safety of deflazacort in diabetic subjects infected with SARS-CoV-2.Multidisciplinary respiratory medicine · 2025
   Article
3. From Legacy to Innovation: Pidotimod's Expanding Therapeutic Horizon.Mediterranean journal of hematology and infectious diseases · 2025
   Review
4. Pidotimod in pediatrics: new evidence and future perspectives.Multidisciplinary respiratory medicine · 2024
   Article
5. Antimicrobial resistance in intensive care patients hospitalized with SEPSIS: a comparison between the COVID-19 pandemic and pre-pandemic era.Frontiers in medicine · 2024
   Article
6. Are monoclonal antibodies effective in patients with severe obesity in SARS-CoV-2 infected?Immunity, inflammation and disease · 2023
   Article
7. Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation.International journal of molecular sciences · 2022
   Article
8. New Therapeutic Options in Mild Moderate COVID-19 Outpatients.Microorganisms · 2022
   Article
9. Molnupiravir as an Early Treatment for COVID-19: A Real Life Study.Pathogens (Basel, Switzerland) · 2022
   Article
10. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.Computational and structural biotechnology journal · 2022
    Review
11. Association of Inflammatory Biomarkers and Cardiovascular Risk Scores in an Italian Cohort of HIV Positive Patient Undergoing Antiretroviral Therapy.Current HIV research · 2022
    Article
12. Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation.Mediterranean journal of hematology and infectious diseases · 2022
    Article
13. Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia.Journal of clinical medicine · 2021
    Article
14. Current treatment strategies for COVID‑19 (Review).Molecular medicine reports · 2021
    Review
15. Attitudes and Intentions toward COVID-19 Vaccination among Spanish Adults: A Descriptive Cross-Sectional Study.Vaccines · 2021
    Article
16. Parameters associated with diagnosis of COVID-19 in emergency department.Immunity, inflammation and disease · 2021
    Observational
17. Normal breathing releases SARS-CoV-2 into the air.Journal of medical microbiology · 2021
    Article
18. An integrative look at SARS‑CoV‑2 (Review).International journal of molecular medicine · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as